Parkinson’s disease

Byaibio

Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by selective loss of dopamine-producing neurons in the substantia nigra, leading to motor and non-motor symptoms; its slow progression means disease-modifying trials need long follow-up to detect slowing. It is strongly linked to pathological alpha-synuclein accumulation, familial and sporadic risk genes such as lrrk2, pink1, and snca, and central mechanisms including mitochondrial dysfunction, disrupted lipid homeostasis, and cGAS-STING–mediated neuroinflammation. Current therapeutic and experimental work spans symptomatic treatment with levodopa, neuroprotective strategies such as sulforaphane, sitagliptin, and vildagliptin, and genome-editing approaches using crispr cas9. Recent studies also highlight gut-brain axis modulation by akkermansia muciniphila, blood microbial signatures associated with progression, and patient-specific metabolite clustering, underscoring PD heterogeneity. Model systems and mechanistic studies include 6-OHDA and MPTP/MPP+ paradigms, while mitochondrial homeostasis, autophagy, and mitochondrial Ca2+ handling remain prominent therapeutic targets. Overall, PD is a major focus of multi-omics research and disease-modifying trial design, with recent literature emphasizing biomarker discovery and pathway-targeted interventions.

Disease mechanisms and biomarkers

  • A 2026 review in Experimental Neurology (PMID:41759571) highlighted mitochondrial dysfunction and disrupted neuronal lipid homeostasis as central mechanisms in Parkinson’s disease pathogenesis.
  • A 2026 Gene review (PMID:41500413) described cGAS-STING activation as an emerging contributor to PD pathogenesis and a potential disease-modifying therapeutic target.
  • A 2026 Microbiological Research review (PMID:41475022) framed akkermansia muciniphila as a double-edged gut-brain axis modulator with life-stage-specific nutritional effects in PD.
  • A 2026 EBioMedicine cross-sectional study (PMID:41864063) reported blood microbial signatures associated with disease progression in PD.
  • A 2026 NPJ Parkinson’s Disease study (PMID:42014729) found heterogeneous metabolite secretion patterns and patient-specific metabolic clustering in PD.

Therapeutics and trial design

  • A 2026 Journal of Parkinson’s Disease review (PMID:41656560) emphasized that the slow rate of progression in PD necessitates long follow-up times to identify evidence of disease slowing.
  • A 2026 Parkinsonism & Related Disorders study (PMID:41734429) investigated molecular analysis of mitochondrial complex I in the levodopa short duration response, reinforcing levodopa as the main symptomatic therapy.
  • A 2026 3 Biotech study (PMID:41853215) reported neuroprotective effects of sitagliptin and vildagliptin via autophagy modulation in PD models.
  • A 2026 Bioorganic Chemistry study (PMID:41797134) showed sulforaphane inhibits NLRP3 inflammasome activation by inducing mitochondrial autophagy and mitigating CBS-H2S axis damage in in-vitro and in-vivo PD models.
  • A 2026 Genes & Diseases study (PMID:41332434) found NAD+ supplementation augments the efficacy of the PARP1 inhibitor PJ34 in a 6-OHDA-induced PD model.

Models, mechanisms, and emerging approaches

  • A 2026 Neurochemistry International review (PMID:41905621) discussed crispr cas9 genome editing as a therapeutic avenue for PD and for creating disease models.
  • A 2026 Neural Regeneration Research review (PMID:41975595) highlighted mitochondrial Ca2+ handling and organelle homeostasis as druggable targets in neurodegenerative diseases, including PD.
  • A 2026 CNS & Neurological Disorders – Drug Targets review (PMID:41918200) placed PD in the context of neuroinflammation and autophagy dysregulation.
  • A 2026 Neuroscience systematic review (PMID:41638346) identified Parkinson’s disease as one of the most frequently studied conditions in multi-omics integration research.
  • Preclinical PD models included 6 ohda (PMID:41332434), mptp (PMID:41853215), and mpp+-induced microglial models (PMID:41853215), supporting mechanistic and therapeutic testing.